A Phase 2b clinical trial of arsenic trioxide for systemic sclerosis
Latest Information Update: 04 Nov 2024
Price :
$35 *
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Sponsors Medsenic
- 28 Oct 2024 According to a BioSenic media release, this trial could be started only if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The start of SLE and SSc Phase II clinical trials is therefore not envisioned before 2025.
- 24 May 2024 According to a BioSenic media release, this trial is still in the planning stage with the protocols for both studies being ready.
- 25 Oct 2023 According to a BioSenic media release, it is now possible to start this study, if the company succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The company start study not envisioned before 2025.